Galantamine

Generic Name: Galantamine

Brand Names: Razadyne

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₁NO_₃

CAS Number: 357-70-0

Unique Ingredient Identifier: 0D3Q044KCA

Background: Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantam...

Indication: Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.

Associated Conditions: Mild to Moderate Dementia Due to Alzheimer's Disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Effects of Galantamine on Cognition

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Galantamine
Drug: Placebo

First Posted Date: 2010-04-09

Last Posted Date: 2022-06-08

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 12

Registration Number: NCT01100775

Locations: 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States

The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Galantamine

First Posted Date: 2010-01-22

Last Posted Date: 2012-12-24

Lead Sponsor: Janssen Korea, Ltd., Korea

Target Recruit Count: 99

Registration Number: NCT01054976

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: BMS-708163
Drug: galantamine

First Posted Date: 2009-12-24

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01039194

Locations: 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

Characteristics of Treatment Responders to Galantamine

Not Applicable

Completed

Conditions: Dementia

Interventions: Drug: galantamine

First Posted Date: 2009-12-09

Last Posted Date: 2016-01-06

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 66

Registration Number: NCT01029132

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Galantamine
Drug: Oxytocin
Other: Placebo-Oxytocin
Other: Placebo-Galantamine

First Posted Date: 2009-11-11

Last Posted Date: 2022-01-12

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 86

Registration Number: NCT01012167

Locations: 🇺🇸
Baltimore VA Medical Center, Baltimore, Maryland, United States
🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States
🇺🇸
Community Mental Health Centers, Baltimore, Maryland, United States

and more 2 locations

Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine

Completed

Conditions: Dementia, Vascular
Dementia
Alzheimer Disease

Interventions: Drug: Galantamine
Drug: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)

First Posted Date: 2009-11-06

Last Posted Date: 2014-06-18

Lead Sponsor: Janssen-Cilag G.m.b.H

Target Recruit Count: 1134

Registration Number: NCT01009476

Galantamine Effects on Cognitive Function in Marijuana Users

Phase 1

Completed

Conditions: Memory

Interventions: Drug: Placebo
Drug: Galantamine

First Posted Date: 2009-09-01

Last Posted Date: 2012-07-25

Lead Sponsor: Yale University

Target Recruit Count: 29

Registration Number: NCT00969696

Locations: 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

Phase 4

Completed

Conditions: Dementia

Interventions: Drug: Galantamine
Drug: Placebo
Drug: Nimodipine

First Posted Date: 2008-12-25

Last Posted Date: 2013-08-26

Lead Sponsor: Janssen-Cilag Farmaceutica Ltda.

Target Recruit Count: 22

Registration Number: NCT00814658

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

Phase 2

Completed

Conditions: Cocaine Dependence

Interventions: Drug: Galantamine
Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT)

First Posted Date: 2008-12-17

Last Posted Date: 2019-01-30

Lead Sponsor: Yale University

Target Recruit Count: 120

Registration Number: NCT00809835

Locations: 🇺🇸
Regional Network of Programs, Stratford, Connecticut, United States
🇺🇸
Kinsella Treatment Center (KTC), Bridgeport, Connecticut, United States

A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Galantamine

First Posted Date: 2008-05-19

Last Posted Date: 2013-09-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 2051

Registration Number: NCT00679627

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy